Literature DB >> 35134144

Chagas Disease Prevalence in a Cohort of Neurocysticercosis Patients in a Nonendemic Setting.

Katherine R McAleese1, Janitzio J Guzmán2, Lauren Thumm2, Thomas B Nutman2, Adrienne Showler2,3, Elise M O'Connell2.   

Abstract

In a cohort of mostly Central American immigrants with confirmed neurocysticercosis (NCC), 3.1% were confirmed positive for Chagas disease (CD). The majority were diagnosed with NCC before age 50. Entry to care for NCC is an opportunity for early detection and possible treatment for CD in those from endemic areas. Published by Oxford University Press for the Infectious Diseases Society of America 2022.

Entities:  

Keywords:  Chagas disease; neurocysticercosis; screening

Mesh：

Year:  2022        PMID： 35134144      PMCID： PMC9477447          DOI： 10.1093/cid/ciac076

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  10 in total

Review 1.  Chagas Disease: Epidemiology and Barriers to Treatment.

Authors:  Roger M Mills
Journal:  Am J Med       Date:  2020-06-24       Impact factor: 4.965

Review 2.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

3.  Chagas disease in Latin America: an epidemiological update based on 2010 estimates.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-02-06

4.  Neurocysticercosis in the United States.

Authors:  Jose A Serpa; A Clinton White
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

5.  Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis.

Authors:  Ana Requena-Méndez; Sheila Bussion; Edelweiss Aldasoro; Yves Jackson; Andrea Angheben; David Moore; Maria-Jesús Pinazo; Joaquim Gascón; Jose Muñoz; Elisa Sicuri
Journal:  Lancet Glob Health       Date:  2017-02-28       Impact factor: 26.763

6.  Morbidity and prognostic factors in chronic chagasic cardiopathy.

Authors:  Manoel Otávio C Rocha; Maria Carmo P Nunes; Antonio L Ribeiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

7.  Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.

Authors:  Yagahira E Castro-Sesquen; Antonella Saldaña; Dhayanna Patino Nava; Tabitha Bayangos; Diana Paulette Evans; Kelly DeToy; Alexia Trevino; Rachel Marcus; Caryn Bern; Robert H Gilman; Kawsar R Talaat
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

Review 8.  Diagnostic criteria for neurocysticercosis, revisited.

Authors:  Oscar H Del Brutto
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

9.  Prevalence of Chagas Disease in the Latin American-born Population of Los Angeles.

Authors:  Sheba K Meymandi; Colin J Forsyth; Jonathan Soverow; Salvador Hernandez; Daniel Sanchez; Susan P Montgomery; Mahmoud Traina
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

10.  Recommendations for Screening and Diagnosis of Chagas Disease in the United States.

Authors:  Colin J Forsyth; Jennifer Manne-Goehler; Caryn Bern; Jeffrey Whitman; Natasha S Hochberg; Morven Edwards; Rachel Marcus; Norman L Beatty; Yagahira E Castro-Sesquen; Christina Coyle; Paula Stigler Granados; Davidson Hamer; James H Maguire; Robert H Gilman; Sheba Meymandi
Journal:  J Infect Dis       Date:  2022-05-04       Impact factor: 7.759
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.